SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla to acquire Inzpera Healthsciences

04 Nov 2025 Evaluate

Cipla has entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences (Inzpera). The company will pay a consideration of around Rs 110.65 crore for acquisition of equity shares and non-convertible redeemable preference shares, representing 100% of Inzpera’s shareholding.

Upon acquisition, Inzpera will become wholly owned subsidiary of the company. The acquisition is a strategic move aimed at combining Inzpera’s extensive portfolio of paediatric pharmaceutical and wellness products with the company’s strong distribution network and operational capabilities to drive growth and scalability.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1232.35 -5.95 (-0.48%)
20-Apr-2026 14:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.90
Dr. Reddys Lab 1234.40
Cipla 1232.35
Zydus Lifesciences 936.50
Lupin 2328.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×